Lexicon to Report Fourth Quarter and Year End 2009 Financial Results on February 23, 2010
February 16 2010 - 6:00PM
PR Newswire (US)
Conference Call and Webcast to Follow THE WOODLANDS, Texas, Feb. 16
/PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc.
(NASDAQ:LXRX), a biopharmaceutical company focused on discovering
and developing breakthrough treatments for human disease, will
release its fourth quarter and year end 2009 financial results on
Tuesday, February 23, 2010 before the financial markets open.
Lexicon management will hold a conference call and webcast to
discuss its clinical development progress and financial results for
fourth quarter and year end 2009 at 11:00 a.m. Eastern Time on
February 23, 2010. The dial-in number for the conference call is
888-220-1244 (within the US/Canada) or 706-679-5615
(international). The conference ID for all callers is 57354686.
Investors can access a live webcast of the call at
http://www.lexpharma.com/. An archived version of the webcast will
be available on the website through April 30, 2010. About Lexicon
Lexicon is a biopharmaceutical company focused on discovering and
developing breakthrough treatments for human disease. Lexicon
currently has five drug candidates in development for autoimmune
disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel
syndrome, all of which were discovered by Lexicon's research team.
Lexicon has used its proprietary gene knockout technology to
identify more than 100 promising drug targets. Lexicon has focused
drug discovery efforts on these biologically-validated targets to
create its extensive pipeline of clinical and preclinical programs.
For additional information about Lexicon and its programs, please
visit http://www.lexpharma.com/. Safe Harbor Statement This press
release contains "forward-looking statements," including statements
relating to Lexicon's growth and future operating results,
discovery and development of products, strategic alliances and
intellectual property, as well as other matters that are not
historical facts or information. All forward-looking statements are
based on management's current assumptions and expectations and
involve risks, uncertainties and other important factors,
specifically including those relating to Lexicon's ability to
successfully conduct preclinical and clinical development of its
potential drug candidates, advance additional candidates into
preclinical and clinical development, obtain necessary regulatory
approvals, achieve its operational objectives, obtain patent
protection for its discoveries and establish strategic alliances,
as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates, that may cause Lexicon's actual
results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
"Factors Affecting Forward-Looking Statements" and "Risk Factors"
in Lexicon's annual report on Form 10-K for the year ended December
31, 2008, as filed with the Securities and Exchange Commission.
Lexicon undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise. DATASOURCE: Lexicon Pharmaceuticals,
Inc. CONTACT: D. Wade Walke, Director, Corporate Communications of
Lexicon Pharmaceuticals, Inc., +1-281-863-3046, Web Site:
http://www.lexpharma.com/
Copyright
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024